Burkitt Lymphoma Clinical Trials

Find Burkitt Lymphoma Clinical Trials Near You

Retrospective Observational Study of Intensive First-Line Treatments for Adult Burkitt Lymphoma at Strasbourg University Hospitals

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Burkitt lymphoma is a rare, highly aggressive B-cell non-Hodgkin lymphoma in adults. Although intensive multi-agent chemotherapy can achieve high complete remission rates, it is associated with substantial toxicity, morbidity, and sometimes treatment-related mortality. This retrospective, single-center observational study aims to characterize the short- and long-term complications of intensive first-line treatment in adults with Burkitt lymphoma managed at Strasbourg University Hospitals. The study will evaluate treatment-related toxicities, overall survival at five years, and progression-free survival at 24 months. Secondary objectives include assessing treatment delays, chemotherapy dose reductions, and their associations with toxicity, disease location at diagnosis, and survival. All eligible adult patients diagnosed with Burkitt lymphoma or managed for this condition at Strasbourg University Hospitals and the ICANS between January 1, 2009, and December 31, 2025, will be considered. The study will use retrospective medical record data, with no a priori sample size calculation because of the rarity of the disease and the single-center design.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Adults aged 18 years or older.

• Patients diagnosed with Burkitt lymphoma at Strasbourg University Hospitals between January 1, 2009, and December 31, 2025, and/or managed by the Hematology Department of Strasbourg University Hospitals or ICANS for Burkitt lymphoma during this period.

• No written objection documented in the medical record to the reuse of personal data for scientific research.

Locations
Other Locations
France
Service d'Hématologie et d'Oncologie - CHU de Strasbourg, France
RECRUITING
Strasbourg
Contact Information
Primary
Marie-Pierre LEDOUX, MD
mariepierre.ledoux@chru-strasbourg.fr
33 3 68 76 74 07
Time Frame
Start Date: 2026-02-11
Estimated Completion Date: 2027-04-11
Participants
Target number of participants: 25
Sponsors
Leads: University Hospital, Strasbourg, France

This content was sourced from clinicaltrials.gov

Similar Clinical Trials